Fig. 3

Elevated lncRNA MBNL1-AS1 represses A549-SP⁺ proliferation, migration, invasion, drug resistance, and sphere formation. a Sphere formation of A549-SP⁺ and A549-SP⁻ cells detected using sphere formation assay. b CD133-positive rate of A549-SP⁺ and A549-SP⁻ cells detected using flow cytometry. c lncRNA MBNL1-AS1 expression of A549-SP⁺ and A549-SP⁻ cells determined using RT-qPCR. d Localization of lncRNA MBNL1-AS1 in A549-SP⁺ verified using FISH. e lncRNA MBNL1-AS1 expression of A549-SP⁺ after lncRNA MBNL1-AS1 overexpression determined using RT-qPCR. f Proliferation of A549-SP⁺ after lncRNA MBNL1-AS1 overexpression detected using CCK-8. g Drug resistance of A549-SP⁺ against anti-tumor drugs after lncRNA MBNL1-AS1 overexpression detected using CCK-8. h Clone formation of A549-SP⁺after lncRNA MBNL1-AS1 overexpression detected using clone formation assay. i Cell invasion of A549-SP⁺ after lncRNA MBNL1-AS1 overexpression detected using transwell assay. j Cell migration of A549-SP⁺ after lncRNA MBNL1-AS1 overexpression detected using scratch test. k Sphere formation of A549-SP⁺ after lncRNA MBNL1-AS1 overexpression detected using sphere formation assay. l Protein levels of Oct4 and ABCG2 in A549-SP⁺ after lncRNA MBNL1-AS1 overexpression assessed using western blot analysis; *p < 0.05 vs. A549-SP⁻ or A549 cells treated with oe-lncRNA MBNL1-AS1. Measurement data were depicted as mean ± standard deviation. Comparisons between two groups were analyzed using unpaired t test. The experiment was repeated three times. Oct4, octamer 4; ABCG2, ATP-binding cassette superfamily G (White) member 2; CCK-8, cell counting kit-8; FISH, fluorescence in situ hybridization; NC, negative control